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Introduction: Adjuvants (for example, aluminum salts) are frequently incorporated in licensed vaccines to enhance
the host immune response. Such vaccines include the pneumococcal conjugate, combinations of diphtheria–tetanus/
acellular pertussis, tetanus– diphtheria/acellular pertussis, hepatitis B, some Haemophilus influenzae type b, hepatitis A,
and human papillomavirus. These preparations have been associated with complicated local adverse events, especially
if administered subcutaneously or intradermally in comparison to deep intramuscular injection. We describe a severe
inflammatory reaction at the site of an injection of 13-valent pneumococcal conjugate vaccine.
Case presentation: A 4-month-old Arab baby boy developed dermal necrotizing granulomatous giant cell reaction at
the injection site (right anterior thigh) of the second dose of 13-valent pneumococcal conjugate vaccine. Ziehl–Neelsen
and periodic-acid Schiff were negative. This reaction probably resulted from improper intramuscular administration
because the first (at 2 months of age) and third (at 10 months of age) doses were uneventful.
Conclusions: Dermal necrotizing granulomatous reactions are a serious complication of the 13-valent pneumococcal
conjugate vaccine. Health care providers need to administer this preparation deeply into a muscle mass. Completing
the vaccine series is an acceptable option. Physicians are encouraged to report their experience with completing
vaccine series following adverse events.
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Introduction of the 7-valent pneumococcal conjugate
vaccine (PCV7) has resulted in a substantial drop in the
rate of invasive pneumococcal disease. However, non-
vaccine serotypes have emerged. The 13-valent pneumo-
coccal conjugate vaccine (PCV13) was subsequently
developed and is currently used in many countries [1].
The safety profile of PCV13 is similar to that of PCV7.
Local reactions are common including tenderness (47%),
swelling (29%), and redness (36%). These adverse events
are usually mild and occur after any dose of the infant
series [2].* Correspondence: alsuwaidia@uaeu.ac.ae
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the site of the injection of the second PCV13 dose. The
report aims at improving vaccination safety.
Case presentation
A 4-month-old previously healthy Arab baby boy pre-
sented with progressive swelling, redness, and firmness
at the injection site (right anterior thigh) of his second
PCV13 dose. The findings were noticeable within 24
hours of the vaccination and progressed rapidly into the
prepatellar area.
At 3 weeks, the clinical findings in the anterior aspect of
his knee were very prominent (Figure 1), prompting drain-
ing of the lesion. The aspirate (10mL) yielded a sterile pus
(Gram stain and bacterial culture were negative). Never-
theless, he received an empiric course of flucloxacillin.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Radiological images of the lesion 3 weeks after administering the 13-valent pneumococcal conjugate vaccine. Panel A: Right
knee X-ray showing anterior fluid collection. Panel B: Ultrasound of the right knee showing swelling (measuring 2.9cm transversely and 1.5cm
anteroposteriorly) of the anterior aspect of the knee due to fluid collection.
Figure 2 Histopathology. Panel A: Low power view (4×): Tissue section of skin demonstrates hyperkeratosis (*), epidermal acanthosis (thickening,
triangle) and an inflammatory dermal process (star). Panel B: Intermediate power view (20×): Dermal granuloma formation accompanied
by multinucleated giant cells (arrows). Panels C-D: High power view (40×): Granulomatous giant cell inflammatory reaction, collection of epithelioid
histiocytes admixed with lymphocytes rimmed by multinucleated giant cells.
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and soft tissue biopsies. The findings revealed erythema
induratum, a granulomatous inflammation with fibrin-
oid and caseous necrosis (Figure 2). Ziehl–Neelsen and
periodic-acid Schiff stains (special stains for mycobacteria
and fungi) were negative. Gram stain showed 3+ pus cells
with no organisms. Wound bacterial culture grew 1+
Klebsiella pneumoniae, considered a secondary infection.
The patient received oral cefixime.
At 10 weeks, the area appeared better; the swelling
and other clinical signs were regressing. He received the
third PCV13 dose at 10 months of age and the injection
was uneventful.Discussion
The precise mechanism of this prolonged and deleteri-
ous inflammatory reaction to PCV13 remains obscure.
Adjuvants, such as aluminum salts, are frequently in-
corporated in licensed vaccines (including PCV13) to
enhance the host immune response [3]. Local reactions
(for example, granuloma formation) induced by these
adjuvants are relatively common [4].
Bordet et al. have reported cases of subcutaneous nod-
ules with a necrotizing granulomatous reaction at the
site of a previous injection of the aluminum hydroxide-
containing vaccine, Tetracoq® (tetanus, diphtheria, Borde-
tella pertussis, poliovirus) [5]. Several cases of persistent
itchy subcutaneous nodules (lasting for years) and hyper-
sensitivity to aluminum after diphtheria–tetanus/acellular
pertussis/polio+Hib vaccination have been also described
[6]. Consistently, one study in pigs demonstrated that
aluminum hydroxide could invoke a granulomatous
reaction [7].
The American Academy of Pediatrics recommends that
administration of vaccines containing adjuvants (for ex-
ample, aluminum present in vaccines recommended for
intramuscular injection including PCV13) should be deep
into a muscle mass. Subcutaneous or intradermal in-
jections of these preparations are associated with an
increased incidence of local irritation, inflammation,
granuloma formation, and tissue necrosis [8].
This baby had no adverse events following the first
and third PCV13 doses. Thus, it is unlikely that the ob-
served response to the second PCV13 dose was an aller-
gic reaction. It is probable that an improper technique of
administration was responsible for this reaction. Proving
this possibility retrospectively, however, is difficult.
The specific stains and cultures did not support myco-
bacterial or fungal infection. The positive wound bacterial
culture was most probably a secondary hospital-acquired
infection and managed with a proper antibiotic. The initial
antibiotic course, however, was empiric for a suspected
cellulitis.Conclusions
Dermal necrotizing granulomatous giant cell reaction is
a serious complication of the 13-valent pneumococcal
conjugate vaccine. These lesions require only conserva-
tive treatment. Babies may react to any dose of the vaccine
series. Physicians are encouraged to report their experi-
ence with completing vaccine series following adverse
events. Appropriate administration technique of adjuvant-
containing vaccines is crucial.
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